ACORI RESEARCH REVIEW: AUGUST 2020

A Message from the President's Task Force

By Randall A. Oyer, MD

Advancing age is the biggest risk factor for cancer. According to the National Cancer Institute, the median age at which cancer is diagnosed in the United States is 66 years. One-quarter of new cancer cases are diagnosed in people aged 65 to 74. An aging population is expanding this demographic trend. By the year 2030, 70 percent of all cancers are expected to occur in adults age 65 and older. Understanding how emerging cancer treatments affect older adults is critical for the delivery of high-quality, patient-centered care.

Yet older adults are consistently precluded from participating in clinical trials for promising new treatments. A 2019 analysis of more than 300 oncology randomized clinical trials found trial participants to be significantly younger than patients in the general population with the same tumor types. Authors of the report published in JAMA Oncology characterize the age disparity they identified as “pervasive and worsening.” In the authors’ analysis of 262,354 participants enrolled in 302 oncology clinical trials between 1994 and 2015, the median age of participants was 6.49 years younger than the median age of other patients with the same cancers.


Featured Clinical Research: The Impact of COVID-19 on Minority Communities

In June, the New England Journal of Medicine published a study by Eboni G. Price-Haywood, MD, MPH, and colleagues, Hospitalization and Mortality among Black Patients and White Patients with Covid-19, that examined EHR patient data from Ochsner Health, an integrated healthcare delivery system, between March 1 and April 11, 2020. Ochsner Health’s self-identified patient demographics are 31% black non-Hispanic and 65% white non-Hispanic. For the study, researchers combed the large health system’s EHR data to identify patients who tested positive for SARS-CoV-2 and to analyze the rates of hospitalization and in-hospital death among COVID-19-positive patients. Of the cohort of 3,481 COVID-19-positive patients eligible for the study, 39% were hospitalized. Three-fourths (76.9%) of patients hospitalized were black. Of the 326 in-patient hospital deaths, 230 (70.6%) occurred in black patients. Study results report that black race, increasing age, a higher score on the Charlson Comorbidity Index, public insurance, residence in a low-income area, and obesity were associated with increased odds of hospitalization. However, when adjusted for sociodemographic and clinical characteristics on admission, black race was not found to be independently associated with higher mortality.


Toward More Inclusive Clinical Trial Eligibility Criteria

Despite the growing number of older adult cancer patients (aged 65 and above), this population has remained under-represented in cancer clinical trials. One way the U.S. Food and Drug Administration (FDA) is working to change the status quo is through guidance documents for industry.


A Focus on Older Adults with Cancer

Each month, we’ll be asking an ACCC member to share their expertise in a specific area of research concentration. In this issue, we asked Ashley Rosko, MD, associate professor in the Department of Internal Medicine at The Ohio State University (OSU), medical director of the oncogeriatric program at the OSU Comprehensive Cancer Center – James, and co-director of the Cancer and Aging Resiliency Clinic at the James to highlight opportunities to augment enrollment of older adults with cancer in cancer clinical trials.